Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Status:
Suspended
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Malignant mesothelioma is a rare neoplasm that arises most commonly from the mesothelial
surfaces of the pleural cavity, occasionally from the peritoneal surface, and rarely from the
tunica vaginalis or pericardium. It has an extremely poor prognosis with a median survival of
4 to 13 months for untreated patients 1 and 6 to 18 months for treated patients, regardless
of the therapeutic approach.
The anticancer activity of Oshadi D and Oshadi R treatment was tested in preclinical studies
and in phase I clinical study. Four metastatic mesothelioma patients are treated for 5 to 12
months. The Oshadi D and Oshadi R combination treatment was generally well-tolerated with no
dose-limiting toxicities observed.